全文获取类型
收费全文 | 282篇 |
免费 | 15篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 8篇 |
妇产科学 | 6篇 |
基础医学 | 18篇 |
口腔科学 | 17篇 |
临床医学 | 45篇 |
内科学 | 55篇 |
皮肤病学 | 11篇 |
神经病学 | 5篇 |
特种医学 | 27篇 |
外科学 | 37篇 |
综合类 | 24篇 |
预防医学 | 13篇 |
眼科学 | 3篇 |
药学 | 21篇 |
肿瘤学 | 11篇 |
出版年
2023年 | 1篇 |
2022年 | 2篇 |
2021年 | 5篇 |
2020年 | 6篇 |
2018年 | 8篇 |
2017年 | 2篇 |
2016年 | 4篇 |
2015年 | 7篇 |
2014年 | 12篇 |
2013年 | 10篇 |
2012年 | 15篇 |
2011年 | 7篇 |
2010年 | 22篇 |
2009年 | 15篇 |
2008年 | 10篇 |
2007年 | 21篇 |
2006年 | 7篇 |
2005年 | 7篇 |
2004年 | 8篇 |
2003年 | 4篇 |
2002年 | 3篇 |
2001年 | 2篇 |
2000年 | 6篇 |
1999年 | 9篇 |
1998年 | 15篇 |
1997年 | 8篇 |
1996年 | 11篇 |
1995年 | 9篇 |
1994年 | 10篇 |
1993年 | 3篇 |
1992年 | 5篇 |
1991年 | 3篇 |
1990年 | 3篇 |
1989年 | 3篇 |
1988年 | 6篇 |
1987年 | 4篇 |
1986年 | 6篇 |
1985年 | 3篇 |
1984年 | 2篇 |
1983年 | 2篇 |
1982年 | 4篇 |
1981年 | 2篇 |
1980年 | 3篇 |
1978年 | 1篇 |
1977年 | 2篇 |
1976年 | 2篇 |
1971年 | 1篇 |
1968年 | 1篇 |
1928年 | 1篇 |
排序方式: 共有303条查询结果,搜索用时 0 毫秒
301.
Glimepiride treatment in a patient with type A insulin resistance syndrome due to a novel heterozygous missense mutation in the insulin receptor gene 下载免费PDF全文
Zhimin Huang Juan Liu Kaka Ng Xuesi Wan Lijuan Xu Xiaoying He Zhihong Liao Yanbing Li 《Journal of diabetes investigation.》2018,9(5):1075-1083
Aims/Introduction
Glimepiride is a sulfonylurea known to have unique insulin mimetic and sensitizing effects. We aimed to study the efficacy of glimepiride in a patient with type A insulin resistance syndrome.Materials and Methods
A 15‐year‐old girl with type A insulin resistance syndrome was treated with glimpiride for 6 months. Self‐monitoring of blood glucose was recorded, and oral glucose tolerance tests on glucose and insulin were measured during the treatment. Hyperinsulinemic euglycemic clamp was used to evaluate whole‐body insulin sensitivity before and after the treatment.Results
A novel heterozygous missense mutation at exon 19 (c.3427A>T) in the tyrosine kinase domain of the INSR gene was identified, causing an amino acid replacement of phenylalanine for isoleucine at codon 1143 (Ile1143Phe). Before the treatment, the patient's glycated hemoglobin was 7.0%, plasma glucose during oral glucose tolerance test was 6.7, 12.8 and 17.3 mmol/L, and simultaneous serum insulin was 80.7, 137.5 and >300 μU/mL. There were no significant differences between self‐monitored blood glucose measured at each time‐point among different glimepiride dosages, or during the 14 weeks when glimepiride was used at its maximal dosage (6 mg/day). Oral glucose tolerance test showed little change in plasma glucose and serum insulin. Glycated hemoglobin decreased by 0.8% after the treatment. However, a euglycemic clamp study showed that the M value decreased from 5.25 to 2.90 mg/kg/min, showing increased insulin resistance.Conclusions
Treatment with glimepiride did not improve insulin sensitivity in a patient with type A insulin resistance syndrome carrying Ile1143Phe heterozygous mutation in the INSR gene. Large‐scale long‐term studies assembled worldwide are required to optimize treatment algorithms for patients with type A insulin resistance syndrome. 相似文献302.
BACKGROUND: Patients with hemophilia B lack factor IX (F IX). These patients may become alloimmunized after the transfusion of F IX concentrates and may develop F IX inhibitors, which have been characterized as polyclonal IgG4 alloantibodies. Two cases in which F IX inhibitors caused difficulty in compatibility testing and antibody identification were encountered. It was hypothesized that, because F IX is present in normal plasma, it might be adsorbed by red cells in vivo and then be detected during antibody screening tests with serum containing F IX inhibitors. CASE REPORT: Sera from two African American half-brothers with hemophilia B were incompatible with all common and rare red cell phenotypes tested in the anti-human globulin test, but did not react with each other's red cells. The brothers' red cell antibodies were neutralized with both normal plasma and a commercially available F IX concentrate, which indicated that the red cell incompatibility was most probably caused by their F IX inhibitors. Red cells from an unrelated patient with hemophilia B and a very low titer of F IX inhibitor were tested against the half-brothers' sera and did not react. The compatible red cells from one of the half-brothers and the unrelated patient with hemophilia B adsorbed F IX from normal plasma or F IX concentrate after 37 degrees C incubation; this rendered them incompatible with the plasma containing F IX inhibitor from the other half-brother. CONCLUSION: F IX appears to be present on normal red cells and may be detected during compatibility and antibody identification procedures when serum or plasma containing F IX inhibitors is tested. 相似文献
303.
Goodman S; Xiao X; Donahue RE; Moulton A; Miller J; Walsh C; Young NS; Samulski RJ; Nienhuis AW 《Blood》1994,84(5):1492-1500
Recombinant adeno-associated viruses (rAAV) containing only the inverted terminal repeats (ITR) from the wild-type virus are capable of stable integration into the host cell genome, and expression of inserted genes in cultured cells. We have now defined the ability of rAAV to introduce genes into primary hematopoietic progenitors. A vector was constructed containing the coding sequences for beta- galactosidase (beta-gal), including a nuclear localization signal, under the control of a strong viral promotor. Infectious vector particles were prepared by cotransfection of the vector plasmid with a second plasmid that contained the coding sequences for AAV proteins into adenovirus-infected human embryonic kidney cells. These vector preparations transferred and expressed the beta-gal gene in human K562 erythroleukemia and Detroit 6 cells. Positive immunoselection yielded a population of enriched CD34+ cells that were transduced with the rAAV beta-gal vector. Nuclear localized enzyme expression was documented in 60% to 70% of infected cells. Progenitor-derived colonies that developed after 2 weeks in clonogenic cultures were shown to have viral- associated DNA at an estimated copy number of 1 to 2 per cell using a semiquantitative polymerase chain reaction (PCR) method. Integration of AAV into hematopoietic progenitors was documented using wild-type virus, as its genome may integrate at a preferred site on chromosome 19. Our data suggest that rAAV will transfer and express genes in primitive hematopoietic progenitors with high frequency, and support the development of this vector system for therapeutic gene transfer. 相似文献